A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy

References

• Minicozzi P, Cassetti T, Vener C, et al. Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates. Cancer Epidemiol. 2018;55:52–60.
   PubMed Web of Science ®Google Scholar
• AIRTUM, AIOM Working Group – The figures of cancer in Italy (I numeri del cancro in Italia), Intermedia ed. 2019.
   Google Scholar
• Primrose JN, Fox RP, Palmer DH, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20(5):663–673.
   PubMed Web of Science ®Google Scholar
• Miyakawa S, Ishihara S, Horiguchi A, et al. Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan. J Hepatobiliary Pancreat Surg. 2009;16(1):1–7.
   PubMedGoogle Scholar
• Jusakul A, Cutcutache I, Yong CH, et al. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7(10):1116–1135.
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arai Y, Totoki Y, et al. Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010.
   PubMed Web of Science ®Google Scholar
• Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. Gastroenterology. 2013;144(4):829–840.
   PubMed Web of Science ®Google Scholar
• Nepal C, O'Rourke CJ, Oliveira DVNP, et al. Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. Hepatology. 2018;68(3):949–963.
   PubMed Web of Science ®Google Scholar
• Jain A, Borad MJ, Kelley RK, et al. Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype. J Clin Oncol Precis Oncol. 2018;2:1–12.
   PubMed Web of Science ®Google Scholar
• Valle JW, Borbath I, Khan SA, et al. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–v37.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Collins GS, Reitsma JB, Altman DG, et al. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. Br J Cancer. 2015;112(2):251–259.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573–577.
   PubMed Web of Science ®Google Scholar
• Brieau B, Dahan L, De Rycke Y, et al. Second-line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine-platinum combination: a large multicenter study by the Association des Gastro-Entérologues Oncologues. Cancer. 2015;121(18):3290–3297.
   PubMed Web of Science ®Google Scholar
• Schweitzer N, Kirstein MM, Kratzel AM, et al. Second line chemotherapy in biliary tract cancer: outcome and prognostic factors. Liver Int. 2019;39(5):914–923.
   PubMed Web of Science ®Google Scholar
• Fornaro L, Cereda S, Aprile G, et al. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer. 2014;110(9):2165–2169.
   PubMed Web of Science ®Google Scholar
• Neuzillet C, Casadei Gardini A, Brieau B, et al. Prediction of survival with second-line therapy in biliary tract cancer: actualisation of the AGEO CT2BIL cohort and European multicentre validations. Eur J Cancer. 2019;111:94–106.
   PubMed Web of Science ®Google Scholar
• Takahara N, Nakai Y, Isayama H, et al. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases. Invest New Drugs. 2018;36(6):1093–1102.
   PubMed Web of Science ®Google Scholar
• Ma L, Qiu J, Zhang Y, et al. Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase, a strong association with survival. OTT. 2018;11:2533–2543.
   Google Scholar
• Park I, Lee JL, Ryu MH, et al. Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer. 2009;115(18):4148–4155.
   PubMed Web of Science ®Google Scholar
• Bridgewater J, Lopes A, Wasan H, et al. Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Ann Oncol. 2016;27(1):134–140.
   PubMed Web of Science ®Google Scholar
• Cho KM, Park H, Oh DY, et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer. Oncotarget. 2017;8(2):2329–2341.
   PubMedGoogle Scholar
• McNamara MG, Templeton AJ, Maganti M, et al. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer. 2014;50(9):1581–1589.
   PubMed Web of Science ®Google Scholar
• Salati M, Filippi R, Vivaldi C, et al. The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. Liver Int. 2020;40(3):704–711.
   PubMed Web of Science ®Google Scholar
• Salati M, Caputo F, Cunningham D, et al. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy. Eur J Cancer. 2019;117:84–90.
   PubMed Web of Science ®Google Scholar
• Park HS, Park JS, Chun YJ, et al. Prognostic factors and scoring model for survival in metastatic biliary tract cancer. Cancer Res Treat. 2017;49(4):1127–1139.
   PubMed Web of Science ®Google Scholar
• Akgül Ö, Bagante F, Olsen G, et al. Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. J Surg Oncol. 2018;118(3):422–430.
   PubMed Web of Science ®Google Scholar
• Buettner S, Spolverato G, Kimbrough CW, et al. The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. Surgery. 2018;164(3):411–418.
   PubMed Web of Science ®Google Scholar
• Zhou LH, Luo XF. Platelet to lymphocyte ratio in biliary tract cancer: review and meta-analysis. Clin Chim Acta. 2017;474:102–107.
   PubMed Web of Science ®Google Scholar
• Hu G, Liu Q, Ma JY, et al. Prognostic significance of platelet-to-lymphocyte ratio in cholangiocarcinoma: a meta-analysis. Biomed Res Int. 2018;2018:1–8.
   Web of Science ®Google Scholar
• Beal EW, Wei L, Ethun CG, et al. Elevated NLR in gallbladder cancer and cholangiocarcinoma - making bad cancers even worse: results from the US Extrahepatic Biliary Malignancy Consortium. HPB. 2016;18(11):950–957.
   PubMed Web of Science ®Google Scholar
• Du JH, Lu J. Circulating CEA-dNLR score predicts clinical outcome of metastatic gallbladder cancer patient. J Clin Lab Anal. 2019;33(2):e22684.
   PubMed Web of Science ®Google Scholar
• Lee BS, Lee SH, Son JH, et al. Neutrophil-lymphocyte ratio predicts survival in patients with advanced cholangiocarcinoma on chemotherapy. Cancer Immunol Immunother. 2016;65(2):141–150.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shi SM, Yang H, et al. Systemic inflammation score predicts survival in patients with intrahepatic cholangiocarcinoma undergoing curative resection. J Cancer. 2019;10(2):494–503.
   PubMed Web of Science ®Google Scholar
• Song W, Zhu ZG, Wu Q, et al. A nomogram to predict overall survival for biliary tract cancer. Cancer Manag Res. 2018;10:1535–1541.
   PubMed Web of Science ®Google Scholar
• Xing KL, Lu LH, Huang X, et al. A novel prognostic nomogram for patients with recurrence of intrahepatic cholangiocarcinoma after initial surgery. Front Oncol. 2020;10:434.
   PubMed Web of Science ®Google Scholar
• Kim BH, Kim K, Chie EK, et al. Risk stratification and prognostic nomogram for post-recurrence overall survival in patients with recurrent extrahepatic cholangiocarcinoma. HPB. 2017;19(5):421–428.
   PubMed Web of Science ®Google Scholar
• Park BK, Paik YH, Park JY, et al. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma. Am J Clin Oncol. 2006;29(2):138–142.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Kan M, Kimura G, et al. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy. J Gastroenterol. 2019;54(3):281–290.
   PubMed Web of Science ®Google Scholar
• McNamara MG, Aneja P, Maganti M, et al. Do recurrent and de novo metastatic biliary tract cancer patients have the same outcome on treatment? Abstract #351, ASCO 2015. J Clin Oncol. 2015;33(3_suppl):351–351.
   Google Scholar
• Kim BJ, Yoo C, Kim KP, et al. Efficacy of fluoropyrimidine-based chemotherapy in patients with advanced biliary tract cancer after failure of gemcitabine plus cisplatin: retrospective analysis of 321 patients. Br J Cancer. 2017;116(5):561–567.
   PubMed Web of Science ®Google Scholar
• Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol. 2014;5(6):428–432.
   PubMedGoogle Scholar
• Rovesti G, Leone F, Brandi G, et al. Prognostic role of a new index tested in European and Korean advanced biliary tract cancer patients: the PECS Index. J Gastrointest Cancer. 2021. DOI:https://doi.org/10.1007/s12029-021-00596-z
   Google Scholar
• Schweitzer N, Fischer M, Kirstein MM, et al. Risk estimation for biliary tract cancer: development and validation of a prognostic score. Liver Int. 2017;37(12):1852–1860.
   PubMed Web of Science ®Google Scholar